At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with ciltacabtagene autoleucel vs standard of care. A retrospective study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results